189O A phase II study of patritumab deruxtecan (HER3-DXd), in patients (pts) with advanced breast cancer (ABC), with biomarker analysis to characterize response to therapy (ICARUS-BREAST01)

Autor: Pistilli, B., Ibrahimi, N., Lacroix-Triki, M., D'Hondt, V., Vicier, C., Frenel, J-S., Dalenc, F., Bachelot, T., Benderra, M-A., Loirat, D., Ducoulombier, A., Mayeur, D., Nachabeh, G.B., Serhal, K., Corcos, N., Sellami, D., Michiels, S., André, F., Mosele, M.F., Montagnac, G.
Zdroj: In ESMO Open May 2023 8(1) Supplement 4
Databáze: ScienceDirect